跳到正文
ECA GMP News·精选AI 评分76

FDA发布药品CGMP检查Form 483观察回复指南草案

FDA Issues Draft Guidance on Responding to Form 483 Observations

AI 导读

FDA发布题为《Responding to FDA Form 483 Observations at the Conclusion of a Drug CGMP Inspection》的指南草案,就药品生产企业如何准备清晰、简洁、有效的Form 483检查观察回复提出建议。

推荐理由

材料列出FDA对Form 483回复常见不足的说明及结构化、基于风险的回复要点,可供读者对照梳理回复思路。

正文 · 原文

The U.S. Food and Drug Administration (FDA) has published a draft guidance titled "Responding to FDA Form 483 Observations at the Conclusion of a Drug CGMP Inspection". The document provides recommendations for pharmaceutical manufacturers on how to prepare clear, concise, and effective responses to inspection observations listed in an FDA Form 483. According to the FDA, responses submitted by companies are often "inadequate". Common problems include missing relevant data, submitting excessive or poorly structured information, or failing to properly address the root cause of the observation. Such responses make it difficult for the agency to assess whether deficiencies have been corrected and whether remediation activities are appropriate. The draft guidance therefore encourages companies to follow a structured and risk-based approach when responding to inspection findings. Firms should evaluate the significance of the observation, identify the underlying root cause, assess potential risks to patients, and implement appropriate corrective and preventive actions. In addition, the guidance provides recommendations on how to handle scientific or technical disagreements with FDA observations. The draft guidance reflects the FDA's current thinking on how manufacturers should respond to Form 483 observations but is not legally binding. Stakeholders may submit comments on the draft guidance by May 8, 2026.

来源:ECA GMP News · gmp-compliance.org